Mabwell's 9MW2821 Posts 30% ORR in ADC-Pretreated TNBC at ESMO
Shanghai – October 18, 2026 -- Mabwell's Nectin-4-targeting antibody-drug conjugate 9MW2821 (Bulumtatug Fuvedotin, "BFv") achieved a 30.0% objective response rate in 60 efficacy-evaluable triple-negative breast cancer (TNBC) patients previously treated with a topoisomerase I (Topo I) ADC, according to Phase II data to be presented orally at the 2026 European Society for Medical Oncology (ESMO) Congress.
Phase II data show 80% disease control and 8.7-month response duration
The study (CTR20242376) evaluates 9MW2821 as monotherapy or combined with a PD-1 monoclonal antibody in locally advanced or metastatic TNBC. Data are as of April 10, 2026.